Literature DB >> 17320833

Cholinesterase inhibitors affect brain potentials in amnestic mild cognitive impairment.

Rie Irimajiri1, Henry J Michalewski, Edward J Golob, Arnold Starr.   

Abstract

Amnestic mild cognitive impairment (MCI) is an isolated episodic memory disorder that has a high likelihood of progressing to Alzheimer's disease. Auditory sensory cortical responses (P50, N100) have been shown to be increased in amplitude in MCI compared to older controls. We tested whether (1) cortical potentials to other sensory modalities (somatosensory and visual) were also affected in MCI and (2) cholinesterase inhibitors (ChEIs), one of the therapies used in this disorder, modulated sensory cortical potentials in MCI. Somatosensory cortical potentials to median nerve stimulation and visual cortical potentials to reversing checkerboard stimulation were recorded from 15 older controls and 15 amnestic MCI subjects (single domain). Results were analyzed as a function of diagnosis (Control, MCI) and ChEIs treatment (Treated MCI, Untreated MCI). Somatosensory and visual potentials did not differ significantly in amplitude in MCI subjects compared to controls. When ChEIs use was considered, somatosensory potentials (N20, P50) but not visual potentials (N70, P100, N150) were of larger amplitude in untreated MCI subjects compared to treated MCI subjects. Three individual MCI subjects showed increased N20 amplitude while off ChEIs compared to while on ChEIs. An enhancement of N20 somatosensory cortical activity occurs in amnestic single-domain MCI and is sensitive to modulation by ChEIs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17320833      PMCID: PMC1933386          DOI: 10.1016/j.brainres.2007.01.120

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  47 in total

1.  Auditory event-related potentials during target detection are abnormal in mild cognitive impairment.

Authors:  Edward J Golob; J K Johnson; A Starr
Journal:  Clin Neurophysiol       Date:  2002-01       Impact factor: 3.708

2.  Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease.

Authors:  R S Doody; J K Dunn; C M Clark; M Farlow; N L Foster; T Liao; N Gonzales; E Lai; P Massman
Journal:  Dement Geriatr Cogn Disord       Date:  2001 Jul-Aug       Impact factor: 2.959

Review 3.  Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease.

Authors:  J C Morris; J L Price
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

4.  Scopolamine reduces the P35m and P60m deflections of the human somatosensory evoked magnetic fields.

Authors:  J Huttunen; I P Jääskeläinen; J Hirvonen; S Kaakkola; R J Ilmoniemi; E Pekkonen
Journal:  Neuroreport       Date:  2001-03-05       Impact factor: 1.837

5.  Effects of stimulus sequence on event-related potentials and reaction time during target detection in Alzheimer's disease.

Authors:  E J Golob; A Starr
Journal:  Clin Neurophysiol       Date:  2000-08       Impact factor: 3.708

6.  Mild cognitive impairment represents early-stage Alzheimer disease.

Authors:  J C Morris; M Storandt; J P Miller; D W McKeel; J L Price; E H Rubin; L Berg
Journal:  Arch Neurol       Date:  2001-03

7.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

Authors:  B Winblad; K Engedal; H Soininen; F Verhey; G Waldemar; A Wimo; A L Wetterholm; R Zhang; A Haglund; P Subbiah
Journal:  Neurology       Date:  2001-08-14       Impact factor: 9.910

8.  Influence of cholinergic circuitries in generation of high-frequency somatosensory evoked potentials.

Authors:  D Restuccia; G Della Marca; M Valeriani; M Rubino; N Paciello; C Vollono; A Capuano; P Tonali
Journal:  Clin Neurophysiol       Date:  2003-08       Impact factor: 3.708

9.  Acetylcholinesterase-rich pyramidal neurons in Alzheimer's disease.

Authors:  S Heckers; C Geula; M M Mesulam
Journal:  Neurobiol Aging       Date:  1992 Jul-Aug       Impact factor: 4.673

10.  Facilitating acquisition and transfer of a continuous motor task in healthy older adults and patients with Alzheimer's disease.

Authors:  Malcolm B Dick; Susie Hsieh; Josh Bricker; Cordula Dick-Muehlke
Journal:  Neuropsychology       Date:  2003-04       Impact factor: 3.295

View more
  3 in total

1.  The impact of AD drug treatments on event-related potentials as markers of disease conversion.

Authors:  Robert M Chapman; Anton P Porsteinsson; Margaret N Gardner; Mark Mapstone; John W McCrary; Tiffany C Sandoval; Maria D Guillily; Lindsey A Reilly; Elizabeth DeGrush
Journal:  Curr Alzheimer Res       Date:  2013-09       Impact factor: 3.498

2.  Cognitive event-related potentials: biomarkers of synaptic dysfunction across the stages of Alzheimer's disease.

Authors:  John M Olichney; Jin-Chen Yang; Jason Taylor; Marta Kutas
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

3.  Musical hallucinations treated with acetylcholinesterase inhibitors.

Authors:  Jan Dirk Blom; Jan Adriaan F Coebergh; René Lauw; Iris E C Sommer
Journal:  Front Psychiatry       Date:  2015-04-07       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.